Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Investor Presentation (July 2024)
24 slides from Telix Pharmaceuticals's investor presentation, Jul 23, 2024
Slide 1: Investor Presentation
For personal use only Investor Presentation 23 July 2024 ASX: TLX Illustration showing TLX250 binding to carbonic anhydrase IX and internalisation
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Telix Pharmaceuticals Limited ACN 616 620 369 (Telix). By attending an investor presentation or briefing, or accepting, accessing or reviewing this presentation, you acknowledge and agree to the terms set out below. This presentation is for informati
Slide 3: A global leader in theranostics and precision medicine
A global leader in theranostics and precision medicine Telix is uniquely positioned in the fast-growing radiopharmaceutical industry For personal use only Integrated theranostic ecosystem Highly differentiated, late-stage Industry-leading assets in prostate, kidney and brain Therapeutics therapeutic
Slide 4: Theranostics: A new, fundamental pillar of oncology
Theranostics: A new, fundamental pillar of oncology Changing the way we find and treat cancer and disease Radiopharmaceuticals deliver targeted radiation directly to tumours, For personal use only limiting damage to surrounding healthy tissue TLX250-CDx: Imaging CAIX Highly selective: Targeting agen
Slide 5: Core pipeline: Key disease areas (alpha and beta emitters)
Core pipeline: Key disease areas (alpha and beta emitters) Dx/ TARGETING AGENT ISOTOPE PHASE 1 PHASE 2 PHASE 3 COMMERCIAL Tx8 For personal use only Antibody 177Lu Tx TLX591 (177Lu rosopatamab tetraxetan) Prostate Antibody α (alpha) Tx PSMA1 TLX592 (alpha-RADmAb®) Small molecule 68Ga Dx TLX591-CDx (6
Slide 6: Precision diagnostics presents a near-term growth opportunity
Precision diagnostics presents a near-term growth opportunity Telix’s imaging portfolio has a U.S. market opportunity of US$3.5B with potential to grow For personal use only Prostate cancer Kidney cancer Brain cancer Total U.S. market Current approved prostate opportunity Diagnosis of ccRCC4, For im
Slide 7: Therapeutics will be the growth engine of radiopharma
Therapeutics will be the growth engine of radiopharma Global market forecast to grow by 18% per annum to reach US$35B in 20311 For personal use only Therapeutics is the fastest growing segment of the global radiopharmaceutical market: Radiodiagnostics and radiotherapeutics growth 2010-31 US$M • In 2
Slide 8: Late-stage therapeutic programs
Late-stage therapeutic programs Highly differentiated assets, with clinical inflection points approaching For personal use only Prostate Kidney Brain LEAD PROGRAMS ⚫ TLX591: rADC1 targeting ⚫ TLX250: rADC targeting CAIX ⚫ TLX101: Small molecule PSMA for treatment of for treatment of ccRCC3 targeting
Slide 9: Supply chain and manufacturing is integral in radiopharma
Supply chain and manufacturing is integral in radiopharma Telix is equipped to deliver patient doses globally For personal use only Expanding in-house development and Vancouver (BC) Liege (BE) Isotope production Quality control production capacity, underpinned by a robust (ARTMS) global supply chain
Slide 10: Strong product take up has driven attractive revenue growth
Strong product take up has driven attractive revenue growth Established track record of strong financial stewardship For personal use only Q2 Key financial metrics (Q1 2024) Revenue (AUD) 2024 Gross margin Operating profit +58% 200 180 189 66% $29M 160 175 US$19M 140 148 62% Q1 2023 $5.6M (US$3.7M)
Slide 11: Our strategy: Four key areas of investment
Our strategy: Four key areas of investment Multiple near-term catalysts ahead For personal use only Progress Advance next Expand Vertically late-stage generation of commercial integrate supply therapeutic alpha imaging chain pipeline theranostics portfolio 2024 H1 2025 IPAX-2 and IPAX-Linz (TLX101)
Slide 12: Our M&A strategy is closely aligned with our strategic priorities
Our M&A strategy is closely aligned with our strategic priorities Inorganic growth provides opportunities to rapidly differentiate and add value For personal use only Adding sought-after resources, capabilities and value-creating assets Focus areas Supply chain and Clinical-stage pipeline Indication
Slide 13: Precision medicine (diagnostics) portfolio
For personal use only Precision medicine (diagnostics) portfolio Illuccix TLX007-CDx PSMA imaging product Illustration of TLX101-CDx binding to LAT1
Slide 14: The Illuccix difference
The Illuccix® difference The leading gallium-based PSMA-PET1 imaging agent in the U.S. For personal use only CLINICAL HIGH-QUALITY C7 Vertebral Left Iliac Fused MIP ACCURACY IMAGES body metastasis metastasis High-quality images PET Pinpoint micrometastases positive at the earliest signs across vital
Slide 15: TLX250-CDx (Zircaix) for imaging of kidney cancer
TLX250-CDx (Zircaix®1) for imaging of kidney cancer A clear value proposition in the diagnosis of clear cell renal cell carcinoma (ccRCC) For personal use only U.S. BLA filing submission complete TLX250-CDx PET (ZIRCON study) • Antibody-based PET imaging agent targeting CAIX (89Zr-girentuximab) • In
Slide 16: TLX101-CDx (Pixclara) for imaging of glioma
TLX101-CDx (Pixclara 1) for imaging of glioma Unmet need for delineating progressive disease from treatment-induced changes For personal use only ROC analysis of 80 Preparing to file U.S. NDA for TLX101-CDx (18F- floretyrosine) patients with grade 3/4 glioma or brain • Small molecule-based PET imagi
Slide 17: CMS proposal to improve payment for precision diagnostics
CMS1 proposal to improve payment for precision diagnostics Facilitates continued patient access once pass-through expires For personal use only Current situation CMS proposal (July 2024) Transitional pass-through (TPT) Unbundled payment, effective January 2025 • For three years, the cost of speciali
Slide 18: Prostate cancer therapy: TLX591
For personal use only Prostate cancer therapy: TLX591 Illustration of TLX591 binding to PSMA
Slide 19: TLX591: Highly differentiated PSMA targeting therapy
TLX591: Highly differentiated PSMA targeting therapy First-in-class / best-in-class radiopharmaceutical therapy using a biologic For personal use only TLX591: rADC for PSMA-expressing mCRPC Lutetium (177Lu) • PSMA is a validated target in prostate cancer1 rosopatamab tetraxetan • TLX591 utilises a P
Slide 20: Potential to overcome limitations of small molecule approach
Potential to overcome limitations of small molecule approach Advantages of the rADC approach Potential benefits for patients, HCPs2 and payors For personal use only Patient friendly, shorter treatment duration DOSING Simple 2-dose regimen Drives mCRPC patient throughput; lowers per patient FLEXIBILI
Slide 21: Biodistribution: TLX591 vs 177Lu-PSMA-617
Biodistribution: TLX591 vs 177Lu-PSMA-617 Visually illustrates durable retention of TLX591 in target tumours For personal use only SPECT TLX591 biodistribution1 SPECT 177Lu-PSMA-617 biodistribution2 4 hours 24 hours 48 hours 120 hours Baseline 4 hours 24 hours 96 hours 168 hours 312 hours Patient re
Slide 22: Summary
For personal use only Summary
Slide 23: Telix is pioneering the next generation of radiopharmaceuticals
Telix is pioneering the next generation of radiopharmaceuticals Uniquely positioned in the fast-growing radiopharmaceutical industry For personal use only • Radiopharmaceutical industry is becoming a fundamental pillar of oncology – market size is forecast to grow to US$35bn by 20311 • Highly differ
Slide 24: Contact details
Contact details: For personal use only Kyahn Williamson SVP Investor Relations and Corporate Communication kyahn.williamson@telixpharma.com
Telix Pharmaceuticals — Investor Presentation (July 2024) on 6ix